Viridian Therapeutics
VRDN
59 hedge funds and large institutions have $72.5M invested in Viridian Therapeutics in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 9 reducing their positions, and 11 closing their positions.
608% more capital inflows, than outflows
Capital inflows: $19.4M | Capital outflows: $2.74M
167% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 9
7.81% more ownership
Funds ownership: 29.63% → 37.44% (+7.8%)
0% more funds holding
Funds holding: 59 → 59 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$8.46M |
| 2 |
BlackRock
New York
|
+$4.11M |
| 3 |
Kennedy Capital Management
St Louis,
Missouri
|
+$1.22M |
| 4 |
State Street
Boston,
Massachusetts
|
+$984K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$758K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$659K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$646K |
| 3 |
Renaissance Technologies
New York
|
-$215K |
| 4 |
Morgan Stanley
New York
|
-$203K |
| 5 |
Goldman Sachs
New York
|
-$146K |
VRDN Hedge Fund Activity: Q2 2018 in Review
59 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2018, worth a combined $72.5M — up 16% from $62.7M a quarter earlier.
Fund positioning in VRDN was balanced in Q2 2018: 11 funds opened new positions, 11 closed out, 24 added to existing stakes and 9 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $8.46M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $659K sold.
- 59 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $72.5M of Viridian Therapeutics stock for Q2 2018, up 16% quarter-over-quarter.
- 11 funds opened new Viridian Therapeutics positions in Q2 2018 and 11 closed out, a net change of 0 holders.
- The largest Viridian Therapeutics buyer in Q2 2018 was Opaleye Management, an estimated $8.46M added.
- The largest Viridian Therapeutics seller in Q2 2018 was Monashee Investment Management, an estimated $659K sold.
Based on aggregated 13F filings for Q2 2018.